IP Library › Granted Patent US 12,702,671
Granted Patent B2
US 12,702,671 · App. 17/820,010 · Granted Aug 11, 2026

Calcineurin inhibitors of the setron family for the treatment of hearing loss

Inventor: Jonas Dyhrfjeld-Johnsen (Lunel-Viel, FR)
Assignee: SENSORION
A61K31/538A61K31/4178A61K31/4184A61K31/46A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,671
App. No.
17/820,010
Filed
Aug 16, 2022
Granted
Aug 11, 2026
Kind
B2
Art Unit
1621
USPC
514/230.5
Abstract

Disclosed is an inhibitor of calcineurin of the setron family for use for treating hearing loss in a subject in need thereof.

Claims (18)

1 . A method for preventing hearing loss in a subject in need thereof, comprising administering to said subject an inhibitor of calcineurin of the setron family selected from azasetron, ondansetron and pharmaceutically acceptable salts thereof,

wherein administration of the inhibitor of calcineurin of the setron family is started prior to the onset of the hearing loss to be prevented.

2 . The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is azasetron or a pharmaceutically acceptable salt thereof.

3 . The method according to claim 1 , wherein said hearing loss is sensorineural hearing loss.

4 . The method according to claim 3 , wherein said sensorineural hearing loss is noise-induced sensorineural hearing loss, age-related sensorineural hearing loss, ototoxic drug-induced sensorineural hearing loss, or idiopathic sensorineural hearing loss.

5 . The method according to claim 3 , wherein said sensorineural hearing loss is noise-induced sensorineural hearing loss or age-related sensorineural hearing loss.

6 . The method according to claim 3 , wherein said sensorineural hearing loss is ototoxic drug-induced sensorineural hearing loss.

7 . The method according to claim 6 , wherein the ototoxic drug inducing sensorineural hearing loss is selected from the group consisting of aminoglycosides, chemotherapeutic agents, loop diuretics, antimetabolites and salicylates.

8 . The method according to claim 1 , wherein said hearing loss is a decrease in hearing of at least about 20 dB over at least three contiguous frequencies.

9 . The method according to claim 1 , wherein said hearing loss is total deafness.

10 . The method according to claim 1 , wherein said hearing loss is unilateral or bilateral.

11 . The method according to claim 1 , wherein said hearing loss is sudden sensorineural hearing loss.

12 . The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is systemically administered, topically administered, or intra-tympanically injected.

13 . The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is administered 1 to 3 times a day.

14 . The method according to claim 1 , wherein the inhibitor of calcineurin of the setron family is administered for at least 30 days.

15 . The method according to claim 4 , wherein administration of the inhibitor of calcineurin of the setron family is started prior to the exposure to a noise or agent that may cause sensorineural hearing loss.

16 . The method according to claim 4 , wherein said sensorineural hearing loss is noise-induced sensorineural hearing loss and wherein administration of the inhibitor of calcineurin of the setron family is started prior to the exposure to a noise that may cause the noise-induced sensorineural hearing loss.

17 . The method according to claim 4 , wherein said sensorineural hearing loss is ototoxic drug-induced sensorineural hearing loss and wherein administration of the inhibitor of calcineurin of the setron family is started prior to the exposure to an agent that may cause the ototoxic drug-induced sensorineural hearing loss.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: DYHRFJELD-JOHNSEN, JONAS
To: SENSORION
Reel/Frame 060824/0072 →
Priority Claims (1)
EP 15167992 · May 18, 2015 · regional
Continuity (3)
Continuation 15574547 · May 18, 2016
Provisional Application 62163177 · May 18, 2015
Related Publication 20220387438A1 · Dec 8, 2022
References Cited (36)
US 4892872A · Tahara · 1990 [cited by examiner]
US 11433077B2 · Dyhrfjeld-Johnsen · 2022 [cited by examiner]
US 11612605B2 · Dyhrfjeld-Johnsen · 2023 [cited by examiner]
US 20030229333A1 · Ashton · 2003 [cited by examiner]
US 20150174148A1 · Brown et al. · 2015 [cited by applicant]
JP 2011528036A · 2011 [cited by applicant]
JP 2015524408A · 2015 [cited by applicant]
WO WO2005000216A2 · 2005 [cited by examiner]
WO WO2009033650A1 · 2009 [cited by examiner]
WO 2010008995A2 · 2010 [cited by applicant]
WO WO2010133633A1 · 2010 [cited by examiner]
WO WO2010133663A1 · 2010 [cited by examiner]
WO 2013124416A1 · 2013 [cited by applicant]
Bas et al., “An experimental comparative study of dexamethasone, melatonin and tacrolimus in noise-induced hearing loss”. Acta Otolaryngol. Apr. 2009;129(4):385-9. [cited by applicant]
Crane et al., “Steroids for treatment of sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials”. Laryngoscope. Jan. 2015;125(1):209-17. [cited by applicant]
Di Leo et al., “Late recovery with cyclosporine-A of an auto-immune sudden sensorineural hearing loss”. Acta Otorhinolaryngol Ital. Dec. 2011;31(6):399-401. [cited by applicant]
Dyhrfjeld-Johnsen et al., “Ondansetron reduces lasting vestibular deficits in a model of severe peripheral excitotoxic injury”. J Vestib Res. 2013;23(3):177-86. [cited by applicant]
Filipo et al., “Oral versus short-term intratympanic prednisolone therapy for idiopathic sudden hearing loss”. Audiol Neurootol. 2014;19(4):225-33. [cited by applicant]
Kramer et al., “Calcineurin controls the expression of numerous genes in cerebellar granule cells”. Mol Cell Neurosci. Jun. 2003;23(2):325-30. [cited by applicant]
Lin et al., “Hearing loss and cognitive decline in older adults”. JAMA Intern Med. Feb. 25, 2013;173(4):293-9. [cited by applicant]
McClelland et al., “Role of ciclosporin in steroid-responsive sudden sensorineural hearing loss”. Acta Otolaryngol. Dec. 2005;125(12):1356-60. [cited by applicant]
Naesens & Sarwal, “Monitoring calcineurin inhibitor therapy: localizing the moving target”. Transplantation. Jun. 15, 2010;89(11):1308-9. [cited by applicant]
Naesens et al., “Calcineurin inhibitor nephrotoxicity”. Clin J Am Soc Nephrol. Feb. 2009;4(2):481-508. [cited by applicant]
Shupak et al., “Otoacoustic emissions in the prediction of sudden sensorineural hearing loss outcome”. Otol Neurotol. Dec. 2014;35(10):1691-7. [cited by applicant]
Uemaetomari et al., “Protective effect of calcineurin inhibitors on acoustic injury of the cochlea”. Hear Res. Nov. 2005;209(1-2):86-90. [cited by applicant]
Vallano et al., “Depolarization and Ca(2+) down regulate CB1 receptors and CB1-mediated signaling in cerebellar granule neurons”. Neuropharmacology. May 2006;50(6):651-60. [cited by applicant]
Venail et al., “A protective effect of 5-HT3 antagonist against vestibular deficit? Metoclopramide versus ondansetron at the early stage of vestibular neuritis: a pilot study”. Eur Ann Otorhinolaryngol Head Neck Dis. Ap… [cited by applicant]
Viberg & Canlon, “The guide to plotting a cochleogram”. Hear Res. Nov. 2004;197(1-2):1-10. [cited by applicant]
Yamashita et al., “Delayed production of free radicals following noise exposure”. Brain Res. Sep. 3, 2004;1019(1-2):201-9. [cited by applicant]
Yang et al., “Quantitative analysis of apoptotic and necrotic outer hair cells after exposure to different levels of continuous noise”. Hear Res. Oct. 2004;196(1-2):69-76. [cited by applicant]
European Search Report, dated Sep. 23, 2015, from corresponding EP 15 167 992.5 application. [cited by applicant]
International Search Report, dated Jun. 21, 2016, from corresponding PCT/EP2016/061119 application. [cited by applicant]
Jackson, L. and Silverstein, H., “Meniere's Disease: Diagnosis, Natural History, and Current Management,” Aug. 19, 2002, https://www.audiologyonline.com/articles/meniere-s-disease-diagnosis-natural-1161, accessed Jan. 2… [cited by applicant]
Shulman, A. and Goldstein, B., “Brain and inner-ear fluid homeostasis, cochleovestibular-type tinnitus, and secondary endolymphatic hydrops,” Int. Tinnitus J, 2006;12(1):75-81, abstract only. [cited by applicant]
Reagan-Shaw, S. et al., “Dose translation from animal to human studies revisited,” The FASEB Journal, vol. 22, Mar. 2007, pp. 659-661. [cited by applicant]
Tsukuda, M. et al., “A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin,” Kagaku Ryoho, 1995, vol. 22, pp. 1959-1967, abstract only. [cited by applicant]